<DOC>
	<DOCNO>NCT00440609</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability Ranibizumab patient Clinically Significant Diabetic Macular Edema ( CSDME ) . It also compare treatment outcome patient receive 0.5mg Ranibizumab high dose 1.0mg 2.0mg Ranibizumab .</brief_summary>
	<brief_title>Study Comparing 0.5mg Ranibizumab Higher Doses Treatment Clinically Significant Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Type I Type II diabetic subject Vision 20/20 20/400 Presence Clinically Significant Diabetic Macular Edema Presence condition would prevent clear visualization back eye Uncontrolled glaucoma Complications glaucoma Inflammation inside eye Certain prior eye surgery , cataract surgery Other eye disease may compromise vision study eye Certain prior eye treatment Pregnancy Uncontrolled health condition History heart attack History stroke Current participation another investigational trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>